In the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study.

Key References:

QUAZAR AML-001: https://pubmed.ncbi.nlm.nih.gov/33369355/
QUAZAR Letter to the Editor: https://pubmed.ncbi.nlm.nih.gov/33789022/

ASH Abstract Data on impact of # of Consolidation Cycles: https://ash.confex.com/ash/2020/webprogram/Paper138498.html
Hovon 97 (Azacitidine SQ maintenance): https://pubmed.ncbi.nlm.nih.gov/30630862/

Mayer, et al. NEJM. 1994. (CALGB HiDAC consolidation): https://pubmed.ncbi.nlm.nih.gov/8078551/
Büchner, et al. JCO. 1985: https://pubmed.ncbi.nlm.nih.gov/3906048/

AML Maintenance Part 1: Set Your QUAZARs to Stun